Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795)

Authors :: Donna S. Cox
T. Gonzalez
Theresa Mays
Amita Patnaik
David S. Hong
R. Kurzrock
Deborah A. Smith
Glenda Chambers
Apostolia-Maria Tsimberidou
L. Rosenstein
J. L. Gauvin
Anthony W. Tolcher
Lon Smith
Douglas J Demarini
Kyri Papadopoulos
Siquing Fu
Shannon R. Morris
Ngocdiep Le
Aung Naing
Gerald Steven Falchook
Source :: Journal of Clinical Oncology. 29:3085-3085
Publication Year :: 2011
Publisher :: American Society of Clinical Oncology (ASCO), 2011.
Abstract: 3085 Background: The RAS/RAF/MEK and PI3K/AKT pathways are activated in many human cancers. GSK212 is a potent and selective allosteric inhibitor of MEK1/2 and GSK795 is a potent ATP-competitive in...

Subjects :: Cancer Research
Oncology
business.industry
Allosteric regulation
Dose escalation
Medicine
Oral Akt Inhibitor GSK2141795
Pharmacology
business
Protein kinase B
PI3K/AKT/mTOR pathway

Tools